GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Quality Rank

Medivir AB (Medivir AB) Quality Rank


View and export this data going back to . Start your Free Trial

What is Medivir AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Medivir AB Quality Rank Related Terms

Thank you for viewing the detailed overview of Medivir AB's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Quality Rank
Comparable Companies
OSTO:SYNACT OSTO:ACE XSAT:HAMLET B XSAT:CURAS OSTO:IVACC OSTO:MAGLE OSTO:CLBIO OSTO:NICA OSTO:IMMU OSTO:SANION OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
MVIR:Sweden MVR0:Germany
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Website
https://www.medivir.com
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.